EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Details Matter in Structure-based Drug Design

Bernd Kuhn, Jens-Uwe Peters, Markus G Rudolph, Peter Mohr, Martin Stahl, Andreas Tosstorff

CHIMIA · 2023

DOI: 10.2533/chimia.2023.489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CHIMIA, 2023. Verfasst von Bernd Kuhn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. bernd.kuhn@roche.com. Hauptthemen laut MEDLINE: Data Mining, Drug Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Successful structure-based drug design (SBDD) requires the optimization of interactions with the target protein and the minimization of ligand strain. Both factors are often modulated by small changes in the chemical structure which can lead to profound changes in the preferred conformation and interaction preferences of the ligand. We draw from examples of a Roche project targeting phosphodiesterase 10 to highlight that details matter in SBDD. Data mining in crystal structure databases can help to identify these sometimes subtle effects, but it is also a great resource to learn about molecular recognition in general and can be used as part of molecular design tools. We illustrate the use of the Cambridge Structural Database for identifying preferred structural motifs for intramolecular hydrogen bonding and of the Protein Data Bank for deriving propensities for protein-ligand interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Data MiningDrug DesignLigandsDatabases, FactualLearning

Stichwörter der Autor:innen

Intramolecular hydrogen bondLigand strainMolecular interactionsPDE10

Substanzen

Ligands

Autor:innen und Institutionen

  • Roche Pharma Research and Early Development, Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. bernd.kuhn@roche.com.
  • Roche Pharma Research and Early Development, Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. jens-uwe.peters@idorsia.com.
  • Roche Pharma Research and Early Development, Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. markus.rudolph@roche.com.
  • Roche Pharma Research and Early Development, Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. peter.mohr@bluewin.ch.
  • Roche Pharma Research and Early Development, Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. c.martin.stahl@gmail.com.
  • Roche Pharma Research and Early Development, Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. andreas.tosstorff@roche.com.

Zitieren

APA

Kuhn, B., Peters, J. U., Rudolph, M. G., Mohr, P., Stahl, M., & Tosstorff, A. (2023). Details Matter in Structure-based Drug Design. CHIMIA. https://doi.org/10.2533/chimia.2023.489

Vancouver

Kuhn B, Peters JU, Rudolph MG, Mohr P, Stahl M, Tosstorff A. Details Matter in Structure-based Drug Design. CHIMIA. 2023. doi:10.2533/chimia.2023.489

BibTeX
@article{Kuhn2023,
  author = {Kuhn, Bernd and Peters, Jens-Uwe and Rudolph, Markus G and Mohr, Peter and Stahl, Martin and Tosstorff, Andreas},
  title = {Details Matter in Structure-based Drug Design},
  journal = {CHIMIA},
  year = {2023},
  doi = {10.2533/chimia.2023.489}
}
Kostenlos starten →